ABSTRACT
Leishmaniosis is a complex disease, with a wide spectrum of clinical manifestation affects over 12 million people globally. Cutaneous leishmaniosis is still an important public health problem in many parts of the world, especially the Middle East. In spite of various forms of local treatment none is generally suitable for all forms of the disease in all. In this reseal-cli, therapeutic effects of paromomycin sulfate in combination with gentamicine sulfate films on cutaneous leishmaniosis in Balb/c mice has been studied. According to data and experiments available in Iran and some endemic countries about treatment of the disease by paromomycin, a new physical form of the drug was designed [drug film] and parasiticidal effects were evaluated in mice model. The base of the fi111is, ethyl cellulose and HPMC [hydroxy propyl Methyl Cellulose] contained paromomyein 15% and gentamicine 0.5%. In this regard female Balb/c mice were infected with 2X l0-6 L. major promastigotes [MRHO/IR/75/ER]. The mice were divided in three groups, of ten mice each. The placebo and test groups were received prepared placebo and drug films respectively. The remaining group, control received no treatment. The results indicated that utilization of this physical form of the drug in a mentioned period of time caused significant cure effects in the test group, so that 80% of Balb/c mice were cured at the end of the treatment period and there was no sign of cure in placebo and control groups. In general and because of good characters of the drug films and related results in animals, it is possible to use the new form of the drug in a human trial